This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Call for Expressions of Interest to host the next ESOT Congress
The European Society for Organ Transplantation (ESOT) invites bids from European countries / cities to host the 2025 or 2027 ESOT Congress. Based on several pre-selection criteria (similar...
ESOT Council – Call for nominations
Dear Colleagues, At the ESOT Congress in Milan, Oriol Bestard, Umberto Cillo, and Frank Dor will complete their term in office as ESOT Councillors....
Webinar: COVID-19 & transplantation – one year on
An assessment of the impact of COVID-19 on transplantation practice, one year from the start of the pandemic.
ESOT multi-organ registry
On March 5th 2021, ESOT opened a tender for a technical provider that will build the multi-organ registry. ESOT is seeking the support of...
New ESOT Member Area!
We are pleased to launch the new ESOT Member Area, an ever-evolving platform from which we are constantly striving to improve the accessibility and...
Technical & Logistical aspects of Performing Normothermic Regional Perfusion in Controlled Donation after Circulatory Death in Europe
A working group of European experts has summarised the current technique and logistical aspects as they are implemented in their countries and / or...
Cell Therapy and Organ Regeneration in Transplantation
REGISTER TODAY – CLICK HERE Registration to 2nd ECTORS Meeting is complimentary, but only registered participants will have access. The Programme is available here
ESOT Congress 2021: Abstract Submission Deadline EXTENDED
The abstract submission deadline for #ESOTcongress has been EXTENDED until Thursday 25th February at 23:59 CET.
The COVID-19 Vaccine Studies
Transplant patients are exceptionally vulnerable to all infections, especially COVID-19, due to immunosuppression and other co-morbidities. There is a clear need for these patients...